Endocrine Abstracts (2009) 19 P106

The challenges of implementing consensus recommendations for GH therapy in GHD adolescent survivors of childhood cancer during the transition period

H Gleeson1, A Whitehouse1, L Smethurst2, S Shalet2, B Brennan2 & P Clayton1,2

1St Mary’s Hospital, Manchester, UK; 2Christie Hospital, Manchester, UK.

Background: Re-evaluation of the diagnosis of GHD at the completion of linear growth is a key task.

Objectives: To audit the impact of consensus recommendations on diagnosis of GHD and initiation of GH therapy in adolescents previously treated for a brain tumour (BT) or haematological malignancy (HM).

Population: Sixty one patients who had received GH therapy until final height following treatment for a BT (n=40) or a HM (n=21) were identified and would be considered within ‘a high likelihood category’ for retesting as GHD (initial IGF-I test, followed by GH test if IGF-I > −2SDS). Of the BT patients 20 had involvement of the hypothalamic pituitary axis (BTHP) and had >3 other pituitary deficits, and by guidelines would not require retesting. Twenty had tumours distant from the HP axis (BTD).

Results: Of the 61 patients, three patients did not attend for retesting. All 20 BTHP patients were eligible for continuous GH therapy without retesting; however, seven were tested, with all except one fulfilling the criteria for GHD (IGF-1 SDS <−2 or peak GH <5 mcg/l). Of the 20 BTD patients 13 had IGF-1 measurements, 7 of whom had an IGF-1<−2 SDS, 5 of these underwent GH provocative testing, all of whom had GH levels of <5 mcg/l. Nine others were diagnosed as GHD on provocative testing. In contrast, of the 21 patients with HM 15 patients had IGF-1 measurements, only one of whom had a level <−2 SDS. Ten were diagnosed as GHD on provocative testing.

After retesting, 46 out of 58 patients were eligible for GH therapy in the transition period. However only 25 eligible patients (54%) restarted or continued GH therapy.

Conclusions: Current guidelines are effective for identifying patients with high likelihood of GHD (IGF-I levels in BT patients), but HM patients require IGF-I and GH testing. However our current endocrine care is failing to educate and encourage adolescents with GHD to restart GH therapy after the completion of growth.

Article tools

My recent searches

No recent searches.